May 9, 2018 05:54 AM EDT
Financing

Evelo Bio grabs $85M as the lat­est ear­ly-stage biotech de­buts on Nas­daq

John Carroll

Editor & Founder

Evelo Bio­sciences be­came the lat­est ear­ly-stage biotech com­pa­ny to make the leap in­to Nas­daq. The Cam­bridge, MA-based com­pa­ny priced 5.3 mil­lion shares at $16 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times